Regeneron Pharmaceuticals
Tarrytown, United StatesFounded 1988
Regeneron Pharmaceuticals is a biotechnology company that invents, develops and commercializes life-transforming medicines. In April 2024, it launched Regeneron Ventures, a corporate venture capital arm with a $500 million commitment to invest in biopharmaceutical, healthcare, and health technology companies.
44% of their portfolio is in Biotech & Life Sciences. They made 2 investments in the last 12 months. Average disclosed round size is $202.1M (across 15 rounds with reported amounts).
Portfolio
12
Fund Size
$500M
Top Stage
Series B
Last 12 Mo
2
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
16 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 TriNetX | Series D | $200M | Apr 2026 |
| AAtavistik | Series B | — | Mar 2026 |
| PParabilis | Series F | $305M | Jan 2026 |
 Parabilis Medicines | Series F | $305M | Jan 2026 |
| AArsenal Biosciences | Series C | $325M | Sep 2024 |
 ArsenalBio | Series C | $325M | Sep 2024 |
| AArsenal Biosciences | Series C | $325M | Jan 2024 |
 Vyriad, Inc. | Series B | $29.5M | May 2022 |
 DNAnexus | Series G | $100M | Jan 2020 |
| AAdicet | Series B | $80M | Oct 2019 |
 Adicet Bio Inc | Series B | $80M | Oct 2019 |
| Adicet Bio Inc | Series B | $80M | Jan 2019 |
 Decibel Therapeutics | Series C | $55M | Jun 2018 |
| AAtavistik | Series A | $100M | — |
| TTasca Therapeutics | Series A | $52M | — |
| PParabilis | Ipo | $670M | — |
Top Co-Investors
ARCH Venture Partners5 shared
RA Capital Management4 shared
Foresite Capital3 shared
DSC Investment3 shared
Pontifax3 shared
Consensus Business Group3 shared
OrbiMed3 shared
Kleiner Perkins3 shared
Bristol Myers Squibb3 shared
GV2 shared
Novartis Venture Fund2 shared
Sixth Street Growth2 shared
Westlake Village BioPartners2 shared
T. Rowe Price2 shared
Hitachi Ventures2 shared
NVentures2 shared
Rock Springs Capital2 shared
Cormorant Asset Management2 shared
Last updated: 20 October 2026